These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 10638398)

  • 1. Bioavailability of intranasal formulations of dihydroergotamine.
    van der Kuy PH; Lohman JJ; Hooymans PM; Ter Berg JW; Merkus FW
    Eur J Clin Pharmacol; 1999 Nov; 55(9):677-80. PubMed ID: 10638398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits.
    Marttin E; Romeijn SG; Verhoef JC; Merkus FW
    J Pharm Sci; 1997 Jul; 86(7):802-7. PubMed ID: 9232520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
    Humbert H; Cabiac MD; Dubray C; Lavène D
    Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations.
    Patel P; Salapatek AM; Talluri RS; Tantry SK
    Allergy Asthma Proc; 2018 May; 39(3):224-231. PubMed ID: 29669667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of nasal powders of beta-cyclodextrin by insufflation.
    De Ascentiis A; Bettini R; Caponetti G; Catellani PL; Peracchia MT; Santi P; Colombo P
    Pharm Res; 1996 May; 13(5):734-8. PubMed ID: 8860429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder.
    Thorsson L; Borgâ O; Edsbäcker S
    Br J Clin Pharmacol; 1999 Jun; 47(6):619-24. PubMed ID: 10383539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline.
    Nau J; Wyatt DJ; Rollema H; Crean CS
    Clin Ther; 2021 Sep; 43(9):1595-1607. PubMed ID: 34456060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat.
    Wang Y; Aun R; Tse FL
    Biopharm Drug Dispos; 1998 Dec; 19(9):571-5. PubMed ID: 9872338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans.
    Chen J; Jiang XG; Jiang WM; Gao XL; Mei N
    Pharmazie; 2005 Jan; 60(1):39-41. PubMed ID: 15702515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.
    Duquesnoy C; Mamet JP; Sumner D; Fuseau E
    Eur J Pharm Sci; 1998 Apr; 6(2):99-104. PubMed ID: 9795022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.
    Vitale DC; Piazza C; Sinagra T; Urso V; Cardì F; Drago F; Salomone S
    Clin Drug Investig; 2013 Dec; 33(12):885-91. PubMed ID: 24085590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2-hydroxypropyl-beta-cyclodextrin on pharmacokinetics of digoxin in rabbits and humans.
    He ZG; Li YS; Zhang TH; Tang X; Zhao C; Zhang RH
    Pharmazie; 2004 Mar; 59(3):200-2. PubMed ID: 15074593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally.
    Van Toor BS; Buchwald A; Stengele E; Trenk D; Gercek C; de Mey CM
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):173-8. PubMed ID: 11332874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.